12505 related articles for article (PubMed ID: 12138657)
1. [Malignant melanoma: diagnostic value of F-18 FDG positron emission tomography].
Aigner RM; Schwarz T; Richtig E
Wien Med Wochenschr; 2002; 152(11-12):286-8. PubMed ID: 12138657
[TBL] [Abstract][Full Text] [Related]
2. Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods.
Krug B; Dietlein M; Groth W; Stützer H; Psaras T; Gossmann A; Scheidhauer K; Schicha H; Lackner K
Acta Radiol; 2000 Sep; 41(5):446-52. PubMed ID: 11016764
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography for staging and management of malignant melanoma.
Prichard RS; Hill AD; Skehan SJ; O'Higgins NJ
Br J Surg; 2002 Apr; 89(4):389-96. PubMed ID: 11952577
[TBL] [Abstract][Full Text] [Related]
4. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
5. Fluorodeoxyglucose positron emission tomography for melanoma staging: refining the indications.
Wagner JD
Ann Surg Oncol; 2006 Apr; 13(4):444-6. PubMed ID: 16491336
[No Abstract] [Full Text] [Related]
6. Malignant melanoma staging using whole-body positron emission tomography.
Paquet P; Hustinx R; Rigo P; Piérard GE
Melanoma Res; 1998 Feb; 8(1):59-62. PubMed ID: 9508378
[TBL] [Abstract][Full Text] [Related]
7. Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma.
Kumar R; Alavi A
Curr Opin Oncol; 2005 Mar; 17(2):154-9. PubMed ID: 15725921
[TBL] [Abstract][Full Text] [Related]
8. Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT.
Akcali C; Zincirkeser S; Erbagcý Z; Akcali A; Halac M; Durak G; Sager S; Sahin E
J Int Med Res; 2007; 35(4):547-53. PubMed ID: 17697533
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy.
Wagner JD; Schauwecker D; Davidson D; Coleman JJ; Saxman S; Hutchins G; Love C; Hayes JT
J Clin Oncol; 1999 May; 17(5):1508-15. PubMed ID: 10334538
[TBL] [Abstract][Full Text] [Related]
10. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma.
Eigtved A; Andersson AP; Dahlstrøm K; Rabøl A; Jensen M; Holm S; Sørensen SS; Drzewiecki KT; Højgaard L; Friberg L
Eur J Nucl Med; 2000 Jan; 27(1):70-5. PubMed ID: 10654150
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
Reinhardt MJ; Joe AY; Jaeger U; Huber A; Matthies A; Bucerius J; Roedel R; Strunk H; Bieber T; Biersack HJ; Tüting T
J Clin Oncol; 2006 Mar; 24(7):1178-87. PubMed ID: 16505438
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosis of metastasis of malignant melanoma in the thyroid gland with f18-FDG PET scan].
Wolf G; Aigner RM; Schwarz T; Nicoletti R
Hautarzt; 2002 May; 53(5):332-3. PubMed ID: 12063745
[TBL] [Abstract][Full Text] [Related]
14. Malignant melanoma and (18)F-FDG-PET: Should the whole body scan include the legs?
Löffler M; Weckesser M; Franzius Ch; Nashan D; Schober O
Nuklearmedizin; 2003 Aug; 42(4):167-72. PubMed ID: 12937695
[TBL] [Abstract][Full Text] [Related]
15. Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node.
Wagner T; Meyer N; Zerdoud S; Julian A; Chevreau C; Payoux P; Courbon F
Br J Dermatol; 2011 Jun; 164(6):1235-40. PubMed ID: 21332457
[TBL] [Abstract][Full Text] [Related]
16. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis.
Rodriguez Rivera AM; Alabbas H; Ramjaun A; Meguerditchian AN
Surg Oncol; 2014 Mar; 23(1):11-6. PubMed ID: 24556310
[TBL] [Abstract][Full Text] [Related]
17. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma.
Crippa F; Leutner M; Belli F; Gallino F; Greco M; Pilotti S; Cascinelli N; Bombardieri E
J Nucl Med; 2000 Sep; 41(9):1491-4. PubMed ID: 10994727
[TBL] [Abstract][Full Text] [Related]
18. FDG PET in early stage cutaneous malignant melanoma.
McIvor J; Siew T; Campbell A; McCarthy M
J Med Imaging Radiat Oncol; 2014 Apr; 58(2):149-54; quiz 266. PubMed ID: 24690243
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma.
Macfarlane DJ; Sondak V; Johnson T; Wahl RL
J Clin Oncol; 1998 May; 16(5):1770-6. PubMed ID: 9586890
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: validation by whole body FDG-PET and conventional diagnostics.
Mruck S; Baum RP; Rinne D; Hör G
Anticancer Res; 1999; 19(4A):2685-90. PubMed ID: 10470220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
